1. Generics Bulletin
  2. >>Business
  3. >>Deals

Glenmark Labels As ‘Speculative’ Report Of Talks To Sell API Unit Stake

 
• By Penelope MacRae

Debt-laden Glenmark Pharmaceuticals has described as “speculative” a report that the firm is discussing with leading Indian family investment office PremjiInvest selling a minority stake in its newly hived-off API subsidiary. The company has promised to remain “proactive” in informing the Bombay Stock Exchange about corporate developments.

Cake
Glenmark Has Addressed Speculation That It Plans To Sell Off A Slice Of Its API Unit • Source: Shutterstock

Ailing Glenmark Pharmaceuticals, which has been seeking to divest a minority stake in its newly spun-off active pharmaceutical ingredient subsidiary to pare its nearly half-billion-dollar debt, has described as “speculative” a media report that it is in discussions with PremjiInvest, the family investment office of Indian software billionaire Azim Premji, about selling 25-30% of the unit for $150m.

Indian financial daily The Economic Times reported that talks were taking place with PremjiInvest, the country’s biggest family office which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Alvotech Boosts Packaging Abilities With Ivers-Lee Acquisition

 
• By Dean Rudge

Alvotech has acquired long-time partner Ivers-Lee to expand its in-house capacity for assembly and packaging ahead of key planned biosimilar launches in 2025, strengthening operational control and supporting global growth.

Lupin And Zentiva Throw Hat Into The Ring On Biosimilar Cimzia

 
• By Dave Wallace

The announcement by Lupin and Zentiva of a development and commercialization deal on a certolizumab pegol biosimilar candidate has revealed a new potential challenger to Alvotech’s AVT10, previously thought to be the only Cimzia rival in development.

China’s Qilu Looks To US Hospitals Market With Sagent Injectables Collaboration

 
• By Dean Rudge

Sagent and Qilu will look to enhance access, reduce treatment costs, and strengthen supply chains after striking an alliance for a portfolio of the Chinese firm’s complex injectables.

Bio Usawa To Market Formycon’s Lucentis Biosimilar In Sub-Saharan Africa

 
• By Urtė Fultinavičiūtė

Bio Usawa’s CEO said access to advanced biologics should not be a privilege of geography or income, as it prepares to launch Formycon/Bioeq’s ranibizumab biosimilar in Africa.

More from Business

Bakers And Fishermen: How Biosimilars Manufacturers Are Bridging The Skills Gap

 
• By Dave Wallace

At Medicines for Europe’s annual conference in Brussels, executives from Polpharma Biologics and Gedeon Richter spoke about the challenges in finding biosimilars manufacturing staff with the right backgrounds – and how they are looking to other industries to bridge the skills gap.

Lupin And Zentiva Throw Hat Into The Ring On Biosimilar Cimzia

 
• By Dave Wallace

The announcement by Lupin and Zentiva of a development and commercialization deal on a certolizumab pegol biosimilar candidate has revealed a new potential challenger to Alvotech’s AVT10, previously thought to be the only Cimzia rival in development.

China’s Qilu Looks To US Hospitals Market With Sagent Injectables Collaboration

 
• By Dean Rudge

Sagent and Qilu will look to enhance access, reduce treatment costs, and strengthen supply chains after striking an alliance for a portfolio of the Chinese firm’s complex injectables.